The investigation, detailed in the Singapore Medical Journal, presents compelling data illustrating that a striking 77 percent of adults experiencing anxiety or depressive symptoms have not sought assistance from mental health professionals such as psychiatrists, psychologists, or social workers. This pervasive reticence underscores the existing barriers within traditional healthcare paradigms, where stigma and apprehension often inhibit proactive engagement. Notably, however, 62 percent of these individuals expressed willingness to engage in peer support mechanisms—a non-clinical, relatable form of assistance emphasizing shared experiences and empathetic connections.

Peer support, as conceptualized in this study, offers an alternative or complementary pathway to conventional mental health services. It provides a relational platform where individuals process their struggles through the lens of communal understanding, potentially remedying what many describe as the intimidating nature of professional care. The preference for peer interactions seems to alleviate psychological barriers through informal and empathetic exchanges, fostering a sense of shared journey and collective resilience that often transcends clinical boundaries.

Moreover, the study delves into the modalities preferred by those receptive to peer support. With 51 percent favoring one-on-one interactions over group settings, and 43 percent indicating a preference for virtual support avenues, there arises a clear mandate to innovate flexible, accessible, and personalized peer-support structures. These preferences highlight the nuanced needs within mental health communities, emphasizing the importance of tailoring programs to individual comfort levels and logistical realities, especially amidst the digital shift catalyzed by modern communication technologies.

Assistant Professor Irene Teo from Duke-NUS’s Lien Centre for Palliative Care underscored the psychological impediments that peer support could help overcome. She highlighted how fear of stigma and judgment cultivates hesitance toward professional help, rendering peer connection—a less formal, more relatable intervention—a potentially transformative solution in mental health outreach. This insight reiterates the significance of designing mental health initiatives that do not merely inform but actively resonate with psychological readiness and emotional safety.

Demographically, the willingness to embrace peer support is stratified by age and occupational factors. Younger adults demonstrate higher acceptance levels, likely reflecting generational shifts marked by increased awareness and destigmatization of mental health issues. Concurrently, those with prior experiences of professional care exhibited greater openness to peer-based alternatives, suggesting a complementary relationship where formal and informal supports coalesce into a holistic continuum of care.

Interestingly, the study also reveals occupational disparities in attitudes toward peer support. Individuals occupying white-collar managerial roles expressed greater receptivity compared to their non-managerial counterparts in clerical or sales positions. This divergence could be attributed to elevated health literacy, compounded stress levels intrinsic to leadership roles, and a deficit of informal support networks in senior professional environments. Such findings prompt reflections on workplace mental health dynamics and the potential for peer-based interventions to mitigate occupational stressors.

The data was systematically garnered via an online survey involving 350 Singaporean adults, integrated within a larger initiative examining the economic ramifications of anxiety and depression. This methodological approach enabled the researchers to capture a representative snapshot of mental health attitudes within a contemporary urban Asian context, facilitating nuanced analyses that bridge epidemiological insights and sociocultural factors.

Professor Eric Finkelstein, the senior author and Executive Director of the Lien Centre for Palliative Care at Duke-NUS, emphasized the imperative for mental health solutions to eschew a monolithic design. Instead, they must incorporate diverse, dynamic elements that balance emotional sustenance, practical guidance, and protective safeguards. His remarks underscore the complexity of mental health care, advocating for systems adaptable enough to reconcile a spectrum of individualized needs and risk profiles.

Confidentiality concerns and skepticism regarding professional care often engender reticence among those in need; thus, peer support heralds an essential component in a comprehensive mental health strategy. By addressing these apprehensions, peer networks can serve as a bridge, fostering initial engagement and preparing individuals for more structured therapeutic interventions when appropriate, hence bridging gaps in accessibility and trust.

Echoing this perspective, Associate Professor Daniel Fung of IMH highlighted how wellbeing evolves antecedent to clinical engagements. He illustrated how many Singaporeans eschew medical labels but deeply yearn to be acknowledged and understood. Peer support, therefore, capitalizes on this humanistic need, facilitating connections that imbue practical coping mechanisms and inspirational narratives rooted in lived experience. Such relational frameworks transcend conventional health services, charting a pathway toward readiness and empowerment.

Professor Sheemei Lok, Duke-NUS’s Interim Vice-Dean for Research, reinforced the communal role in mental health landscapes. By deciphering the contexts and formats through which individuals feel safe seeking help, her commentary stresses the import of designing inclusive and empathetic infrastructures that collaboratively amplify professional care’s reach and efficacy.

This study’s implications extend beyond Singapore’s borders, providing a scalable model for integrating peer support into mental health ecosystems globally. As mental health challenges intensify worldwide, harnessing community-centered interventions that prioritize accessibility, relatability, and adaptability may fundamentally transform public engagement with mental health services. The research heralds a paradigm shift from isolated clinical applications toward hybridized care systems that collectively address multifaceted psychosocial dimensions of mental illness.

Ultimately, this investigation underscores how mental health is intricately woven into social fabric, individual psychology, and cultural attitudes. By recognizing peer support as a vital adjunct to clinical care, healthcare systems can better facilitate early intervention, reduce stigma, and empower individuals in their journeys toward recovery and sustained wellbeing. The evolving narrative positions peer support not merely as a supplementary service but as an integral pillar within a holistic and person-centered mental health framework.

Subject of Research: People

Article Title: Interest in peer support among Singaporean adults with symptoms of anxiety and depression

News Publication Date: 23 June 2026

Web References:
https://journals.lww.com/smj/fulltext/9900/interest_in_peer_support_among_singaporean_adults.274.aspx

References:
DOI: 10.4103/singaporemedj.SMJ-2025-104

Image Credits: Duke-NUS Medical School

Keywords: Mental health, depression, anxiety, peer support, community-based care, Singapore, psychological barriers, stigma, informal mental health care

The rising prevalence of mental health challenges within family units has precipitated urgent demands for accessible, effective, and low-cost intervention models. Traditional face-to-face therapeutic approaches, while valuable, often grapple with limitations such as geographic barriers, cost-prohibitive structures, and stigma associated with seeking psychological help. Harnessing the power of digital platforms circumvents many of these obstacles, delivering therapeutic content to users worldwide without compromising quality. LightBEAM emerges from this paradigm shift as a meticulously crafted platform grounded in evidence-based psychological theories, aiming to catalyze lasting improvements in family functioning and individual wellbeing.

Technically, LightBEAM is devised as a randomized waitlist control trial—the gold standard in clinical research—allowing researchers to rigorously assess intervention efficacy while ethically providing access to participants over time. The protocol involves enrolling families who experience varying degrees of psychological distress or relational dysfunction and randomly allocating them to either immediate access to the program or a delayed access group serving as a control. Such a design enables a robust comparison of outcomes, including stress reduction, communication enhancement, and emotional regulation, while adhering to stringent methodological standards essential for reproducibility and validity.

Central to the LightBEAM intervention are modular components that employ cognitive-behavioral therapy (CBT) principles, mindfulness training, and psychoeducation to cultivate adaptive coping mechanisms and emotional intelligence. The modules are structured to guide participants through progressively challenging tasks, encouraging reflection, self-monitoring, and behavior modification in real time. Interactive elements like quizzes, journaling prompts, and virtual coaching reinforce learning and foster engagement—a critical factor in digital intervention success. Additionally, algorithms analyze user progress and dynamically personalize content delivery, optimizing therapeutic impact according to individual family profiles.

From a technological perspective, LightBEAM leverages advances in user interface design and data encryption to create a secure, intuitive, and aesthetically appealing environment conducive to sustained participation. The platform is cross-compatible with multiple devices, ensuring families can access resources anytime, anywhere. Backend analytics provide researchers with granular data on adherence patterns, module completion rates, and participant feedback, informing iterative refinements to improve user experience and intervention potency. Importantly, LightBEAM incorporates privacy safeguards that comply with the latest ethical standards and data protection regulations, ensuring confidentiality and trust.

One of the groundbreaking aspects of LightBEAM lies in its scalability and potential to bridge gaps in current mental health service delivery. By harnessing the vast reach of the internet, the program transcends socio-economic and geographic boundaries, offering evidence-based resources to underserved populations hitherto marginalized in mental health discourse. This democratization aligns with global health priorities emphasizing mental health equity and universal access. Early pilot data indicate promising adherence rates and participant satisfaction, suggesting that digital interventions like LightBEAM could play a pivotal role in reshaping public health strategies around family wellbeing.

The LightBEAM trial is also notable for its integrative approach, combining quantitative measures such as psychometric scales with qualitative feedback collected through virtual focus groups. This mixed-methods framework enables an enriched understanding of how families internalize and apply intervention content in real-life contexts. Evaluations extend beyond symptom reduction to assess relational metrics, parenting styles, and family resilience, underscoring the program’s holistic conception of wellbeing. The inclusion of diverse demographic cohorts enhances generalizability and aids in identifying subgroup-specific intervention effects.

At the research forefront, the LightBEAM protocol confronts complex challenges inherent in digital psychology interventions. Dropout attrition, inconsistent engagement, and variations in technological literacy pose significant hurdles. To mitigate these, LightBEAM integrates motivational nudges via automated reminders and gamification elements that incentivize progress. The randomization process accounts for baseline heterogeneity by stratifying participants based on key variables, ensuring balanced group comparisons. Robust statistical analyses employing intention-to-treat principles are planned to derive valid inferences, strengthening the evidence base for MOOIs.

Ethical considerations are paramount in deploying internet-based mental health programs. The LightBEAM study emphasizes informed consent procedures that transparently outline risks and benefits, safeguarding participants’ autonomy. Given the remote nature of delivery, protocols for crisis management and referral pathways are embedded to promptly address emergent psychological risks encountered by participants. These safeguards reflect conscientious adherence to ethical frameworks governing human subjects research, a non-negotiable in advancing psychological science responsibly.

Beyond the immediate scope, the implications of the LightBEAM intervention resonate across multiple domains. Its success could serve as a catalyst for developing analogous programs tailored to other populations, such as adolescents, elderly caregivers, or couples therapy cohorts. The methodological innovations realized in constructing and implementing this trial provide a template adaptable to varied clinical and community contexts. Moreover, insights gleaned from engagement analytics could inform the design of future digital therapeutics, enhancing personalization capabilities and user retention.

The advent of LightBEAM reaffirms the burgeoning synergy between psychological science and technology, opening new frontiers for mental health interventions that are simultaneously accessible, effective, and scalable. While challenges remain in optimizing digital delivery and ensuring equitable access, the LightBEAM program protocol serves as a beacon demonstrating the feasibility and promise of Massive Online Open Interventions. As the trial progresses, it will undoubtedly yield critical data advancing our understanding of how virtual platforms can fundamentally transform family wellbeing promotion.

Looking ahead, integrating artificial intelligence with MOOIs like LightBEAM presents opportunities to enhance adaptive learning and real-time feedback mechanisms further. The integration of biometric sensors or passive data collection could provide richer behavioral insights, leading to more nuanced intervention tailoring. Collaborations across disciplines—combining clinical psychology, computer science, and data analytics—will be essential in harnessing these emerging capabilities. The LightBEAM trial thus represents a foundational step into an era of digitally mediated family health enhancement, poised to impact both clinical practice and public health policy profoundly.

Concurrently, the sociocultural dimensions of digital mental health interventions warrant ongoing attention. LightBEAM’s design acknowledges cultural sensitivity and inclusivity, yet continuous evaluation is necessary to ensure relevance across diverse populations. Addressing digital divide issues remains critical, as does fostering trust in technology-mediated care. Stakeholder engagement—including families, clinicians, and policymakers—will be instrumental in refining and disseminating these innovations globally. This multidisciplinary collaboration will facilitate the translation of LightBEAM’s findings into scalable real-world solutions.

In sum, the LightBEAM program protocol encapsulates a compelling vision for advancing family wellbeing through innovative digital platforms. It balances the rigor of randomized controlled trial methodologies with the accessibility and flexibility of online delivery. This approach holds profound potential to surmount traditional barriers in mental health care, offering a scalable model that could redefine family intervention paradigms worldwide. Emerging data from this ambitious trial are eagerly awaited by the scientific community and public health stakeholders alike, illuminating pathways to healthier, more resilient family systems in the digital age.

Subject of Research: Family wellbeing through digital mental health interventions

Article Title: Advancing family wellbeing through a Massive Online Open Intervention: the LightBEAM program protocol for randomized waitlist control trial

Article References: Sitka, M., Simpson, K.M., Paton, A. et al. Advancing family wellbeing through a Massive Online Open Intervention: the LightBEAM program protocol for randomized waitlist control trial {1a}. BMC Psychol (2026). https://doi.org/10.1186/s40359-025-03326-3

Image Credits: AI Generated

Depression is notoriously common among individuals receiving hemodialysis, with prevalence rates significantly higher than in the general population. The psychological burden introduced by chronic kidney disease, compounded by the intensive time commitment and physical toll of dialysis, often results in diminished quality of life and worsened clinical outcomes. Traditional mental health interventions, while effective, face barriers including limited access, stigma, and the physical limitations imposed by treatment schedules. The introduction of a mobile platform leveraging audio-guided CBT techniques represents an adaptive strategy designed to overcome these barriers by offering accessible, scalable, and patient-centric mental health care.

The technical architecture of the app integrates core CBT principles delivered entirely through an audio interface, minimizing the necessity for visual interaction which can be taxing for patients frequently connected to medical devices. This choice of modality is purposeful, recognizing the cognitive and sensory fatigue common in hemodialysis patients. The app’s interface emphasizes simplicity, enabling users to engage with therapy sessions during dialysis or at home without extensive navigation, thereby fostering higher engagement rates and adherence. The developers undertook a user-centered design approach, drawing from extensive qualitative input from patients and clinicians to tailor content and functionality to real-world needs.

The usability evaluation, conducted through a mixed-methods framework, combined quantitative metrics such as task completion rates and error frequencies with qualitative feedback focusing on user satisfaction, perceived effectiveness, and emotional resonance of the therapeutic content. Participants reported that the app’s audio sessions facilitated a calming mindset and provided actionable strategies to manage depressive symptoms. Notably, the on-demand accessibility of the therapy allowed patients to contextualize and apply cognitive restructuring techniques during moments of heightened emotional distress, marking a significant advancement over traditional therapy delivery models that require scheduled sessions.

One of the most compelling features of this innovation lies in its potential to reduce the stigma associated with mental health treatment in somatic illness contexts. By offering a discreet, private platform that patients can utilize independently, the app addresses concerns about social judgment and confidentiality that frequently deter engagement. Furthermore, the audio-based CBT program is structured to empower patients with self-management tools, fostering a sense of autonomy critical to sustained mental health improvement. This aligns with contemporary trends in digital therapeutics, which advocate for patient agency as a cornerstone of effective intervention.

The deployment of this app within dialysis centers also signifies a novel integration of mental health support within somatic care environments. Clinicians involved in the study reported that the app could serve as an adjunct to routine medical treatment, potentially facilitating earlier detection and intervention for depressive symptoms. The researchers envision a future where this technology is embedded in comprehensive care models, augmenting multidisciplinary approaches to chronic kidney disease management. This integration not only promises to enhance patient well-being but may also contribute to improved treatment adherence and overall clinical prognosis.

From a technological standpoint, the backend of the application employs adaptive algorithms to personalize session progression based on user interaction patterns and feedback, promoting relevance and sustained engagement. This dynamic customization is a significant advancement over static digital therapies, which often suffer from high dropout rates due to perceived irrelevance or monotony. The data emerging from this pilot study suggests that patients responded favorably to these tailored pathways, which enhanced the sense of a therapeutic alliance even in the absence of live clinician interaction.

Beyond usability, the researchers conducted preliminary psychometric assessments to explore potential efficacy markers. While the primary aim of the study was to establish feasibility, early indications of mood improvement were observed, correlating with session frequency and consistency of app usage. These findings pave the way for larger clinical trials aimed at rigorously evaluating the therapeutic impact of audio-based mobile CBT in hemodialysis populations. The prospect of a low-cost, scalable digital intervention capable of mitigating depressive symptoms holds substantial implications for public health, especially in resource-limited settings.

The research team also acknowledged the challenges inherent in deploying digital mental health solutions among a medically and demographically heterogeneous group. Variations in age, education level, and technological literacy necessitated the development of comprehensive onboarding processes, including easy-to-follow tutorials and technical support mechanisms. This attentiveness to user diversity underscores the importance of inclusivity in digital health innovation and suggests best practices for future developments targeting similarly complex patient cohorts.

Security and privacy considerations were paramount throughout the app’s design, with stringent encryption protocols safeguarding sensitive user data. Recognizing the sensitive nature of psychological health information, the app’s compliance with healthcare data protection regulations was ensured, and transparent data usage policies were communicated to users. This focus not only supports ethical standards but also builds user trust—an essential component in digital therapeutic success.

Another intriguing aspect of the app is its potential adaptability to other chronic disease populations facing parallel psychological burdens. The modular nature of the audio content facilitates customization for diseases such as diabetes or heart failure, where depression prevalence also adversely impacts outcomes. This adaptability could transform the digital CBT landscape, offering a versatile therapeutic platform with broader applicability beyond its initial scope.

Given the rigorous usability validation and positive patient reception, healthcare providers and policymakers are encouraged to consider the integration of such digital therapeutics into existing mental health infrastructure. The scalability of mobile health solutions could address systemic gaps in psychiatric service accessibility, particularly in rural or underserved areas with limited specialized care. As mobile device penetration continues to surge globally, these audio-based interventions herald a new era where mental health care becomes ubiquitous, patient-friendly, and seamlessly integrated into chronic illness management.

Looking forward, the researchers advocate for iterative refinement based on real-world user data, including enhancements in interactivity and incorporation of biometric feedback to more dynamically respond to patient states. The fusion of machine learning to optimize therapeutic content flow and predictive analytics to identify relapse signals represents an exciting frontier that could further personalize and amplify treatment benefits. This study, therefore, lays foundational groundwork for a future where digital mental health tools not only support but actively augment clinical decision-making and patient self-care.

The convergence of technology, psychology, and nephrology embodied by this audio-based CBT app exemplifies the interdisciplinary innovation necessary to tackle complex health challenges. By harnessing the accessibility of mobile platforms and the evidence-based efficacy of cognitive behavioral therapy, the team has charted a novel path toward holistic, patient-centered care. As the global burden of chronic kidney disease and depression continues to climb, such pioneering solutions are critical to enhancing patient quality of life and mitigating the extensive healthcare costs associated with comorbid mental health disorders.

In conclusion, this study heralds a transformative approach to mental health management in chronic disease settings, offering robust evidence that audio-based mobile CBT is not only feasible and well-received but also holds significant promise for improving depression outcomes in hemodialysis patients. The implications extend far beyond this specific patient cohort, suggesting a scalable model for digital mental health interventions poised to reshape clinical practice worldwide. Continued research and collaborative engagement among technologists, clinicians, and patients will be essential to realize the full potential of this promising innovation.

Subject of Research:
Development and usability evaluation of an audio-based cognitive behavioral therapy mobile app aimed at managing depression in hemodialysis patients.

Article Title:
Development and usability evaluation of an audio-based cognitive behavioral therapy mobile app for depression in hemodialysis patients.

Article References:
Narimanpour, F., Pirnejad, H., Makhdoomi, K. et al. Development and usability evaluation of an audio-based cognitive behavioral therapy mobile app for depression in hemodialysis patients. BMC Psychol (2025). https://doi.org/10.1186/s40359-025-03732-7

Image Credits: AI Generated

Suicide remains a leading cause of death among adolescents and young adults globally, with significant social and economic consequences. In Nepal, cultural stigma, limited mental health resources, and linguistic barriers compound the difficulties in implementing effective psychiatric screening and intervention. Traditional screening instruments, while validated in Western contexts, often fail to translate seamlessly across cultures and languages. This gap has historically hindered early detection of suicidal ideation or behaviors during medical hospitalization, a premium time for clinical intervention.

Responding to this critical void, researchers conducted a comprehensive cross-sectional validation study focusing on the Nepali adaptation of the Ask Suicide-Screening Questions (ASQ) tool. The ASQ, originally developed by the National Institute of Mental Health, is prized for its brevity and efficacy in detecting suicide risk. However, prior to this study, its utility among Nepali-speaking inpatient youth remained untested, limiting its clinical applicability in the region. The investigative team sought not only to adapt the tool linguistically but also to rigorously evaluate its psychometric properties against established clinical benchmarks.

The study enrolled 309 participants aged between 10 and 24 years from two major urban hospitals in Nepal, ensuring a representative sample of medical inpatients. These individuals underwent screening by trained nursing personnel employing the newly translated ASQ questionnaire. Importantly, the participants also completed the adolescent version of the Patient Health Questionnaire-9 (PHQ-9), a recognized instrument to assess depression severity known to correlate with suicidal ideation. This multi-layered approach allowed for a nuanced understanding of mental health status alongside suicidal risk detection.

Central to validating the ASQ’s accuracy was the use of a blind brief suicide safety assessment (BSSA) conducted by clinical psychologists. The BSSA served as the gold standard comparator, providing an objective framework to evaluate the screening tool’s sensitivity and specificity. By employing experts who were not influenced by ASQ results, the study minimized bias and strengthened the robustness of its findings.

The results revealed that 15.9% of participants screened positive for suicide risk using the ASQ, while 8.4% were identified as having elevated suicide risk via the BSSA. Crucially, the ASQ demonstrated commendable diagnostic performance: a sensitivity rate of 77%, suggesting a strong ability to correctly identify individuals at risk, and a specificity rate of 90%, indicating effectiveness in correctly excluding those not at risk. The positive predictive value stood at 41%, reflecting the proportion of true positives among those flagged by the ASQ, and the negative predictive value was notably high at 98%, underscoring the tool’s reliability in ruling out suicide risk.

These psychometric indicators affirm that the Nepali ASQ is both a valid and efficient instrument for suicide risk screening in hospitalized youth populations. Its brevity ensures that it can be feasibly integrated into routine clinical workflows without causing significant additional burden on healthcare staff. Moreover, early identification facilitated by such a tool could lead to timely referrals and interventions, potentially reducing suicide rates in this at-risk group.

Beyond validation, the study’s context highlights important implications for healthcare policy and practice in Nepal. Incorporating culturally adapted, linguistically appropriate screening methods addresses long-standing barriers in mental health care delivery. The integration of such tools during hospitalization—when patients are already engaged with healthcare systems—represents a practical touchpoint to bridge detection and treatment, especially in low-resource environments where psychiatric services are scarce.

Importantly, the researchers advocate for broader implementation and further validation in diverse settings, including outpatient clinics and community health centers. Extending the utility of the Nepali ASQ could facilitate comprehensive surveillance of suicide risk across multiple healthcare touchpoints, advancing public health surveillance and preventive care frameworks.

The study also underscores the vital role that trained nursing personnel and mental health professionals play within multidisciplinary teams. Effective suicide screening hinges on skilled administration, sensitive communication, and appropriate follow-up actions. Capacity-building initiatives aimed at equipping frontline healthcare workers with necessary tools and knowledge are therefore essential components of systemic suicide prevention strategies.

While the ASQ’s validation marks a significant advancement, mental health stakeholders recognize the necessity for ongoing research and refinement. Factors such as cultural perceptions of suicide, stigma, and family dynamics must be considered when interpreting screening outcomes and designing subsequent interventions. Combining quantitative screening tools with qualitative assessments could yield more comprehensive understandings of risk profiles.

This innovative research represents a paradigm shift in suicide prevention efforts within Nepal. By providing a scientifically validated, culturally tailored screening mechanism, it empowers healthcare professionals to better identify vulnerable youth and implement critical interventions during hospital stays. The potential ripple effects extend beyond individual patients to families and communities, fostering resilience and hope in the face of a daunting mental health challenge.

As the global community rallies to meet the United Nations Sustainable Development Goals on health and well-being, projects like the Nepali ASQ validation exemplify the synergy between research, clinical practice, and public health policy. Continued investment in such culturally sensitive tools and their implementation could herald a new era in reducing youth suicide rates in Nepal and similar contexts worldwide.

Looking ahead, researchers emphasize that integrating suicide screening tools with expanded mental health services—such as counseling, crisis intervention, and follow-up care—will be critical. Building infrastructure that supports these interventions requires collaboration across government agencies, healthcare institutions, non-governmental organizations, and community leaders. Embracing a holistic, patient-centered approach stands as the cornerstone of effective suicide prevention.

In summary, the validation of the Nepali version of the Ask Suicide-Screening Questions tool offers a robust, evidence-based foundation to enhance suicide risk assessment among medical inpatients aged 10 to 24 years in Nepal. This pioneering work not only addresses a previously unmet clinical need but also paves the way for systemic changes in mental health screening and intervention. As Nepal and the wider global health community continue to battle the tragic consequences of youth suicide, such innovations provide much-needed tools to save lives and nurture futures.

Subject of Research: Validation of the Nepali version of the Ask Suicide-Screening Questions (ASQ) tool for suicide risk detection among youth medical inpatients.

Article Title: Validity of the Nepali Ask Suicide Screening Questions tool for medical inpatients

Article References:
Poudel, D.R., Sharma, A.K., Chapagain, R.H. et al. Validity of the Nepali Ask Suicide Screening Questions tool for medical inpatients. BMC Psychiatry 25, 719 (2025). https://doi.org/10.1186/s12888-025-07148-w

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07148-w

The therapeutic use of psychedelics is far from new. Between the 1950s and early 1970s, over 40,000 participants took part in clinical studies exploring psychedelics’ promise for treating a range of psychiatric disorders, amassing a substantial corpus of research—over 1,000 published articles—that is virtually forgotten today. Dr. Ross emphasizes that this significant body of knowledge disappeared from psychiatric curricula and clinical practice following the Controlled Substances Act of 1970, which criminalized these compounds and effectively stymied research. This historical oversight, he explains, led to a profound gap in psychiatric education, leaving an entire generation of clinicians unaware of psychedelics’ therapeutic potential.

Dr. Ross’s NYU Psychedelic Research Group, founded in 2006, aimed to revive and expand this promising domain. Among his most notable studies is the landmark 2016 randomized controlled trial that examined psilocybin-assisted psychotherapy for patients with advanced cancer suffering from anxiety, depression, and existential distress. This trial was groundbreaking not only for its scientific rigor but also for its profound findings: a single psilocybin session, when combined with supportive psychotherapy, yielded rapid, sustained alleviation of psychological symptoms. The results resonated widely, captivating public and scientific audiences alike, and earning front-page coverage in the New York Times.

What made these findings particularly remarkable was the speed and durability of clinical improvement observed after just one dose of psilocybin. Unlike conventional psychiatric medications—which typically require daily administration over extended periods—psilocybin induced profound transformations in mood, anxiety, and existential well-being within hours that persisted for months. Approximately 75% of participants rated their psychedelic experience as one of the most meaningful and memorable of their lives, underscoring the depth of the intervention’s impact. These findings challenge prevailing paradigms in psychiatry by suggesting that a small number of psychedelic-assisted sessions may catalyze long-lasting changes in brain and mind.

Building on the success of cancer-related distress studies, Dr. Ross expanded his investigations into other difficult-to-treat psychiatric conditions. Notably, his 2022 JAMA Psychiatry-published clinical trial explored psilocybin-assisted psychotherapy for alcohol use disorder. This study revealed significant reductions in heavy drinking days following just two psilocybin sessions combined with psychotherapy, effects that persisted over an eight-month follow-up period. Such findings open promising avenues for addictions treatment, a notoriously challenging field where existing pharmacological and behavioral interventions often yield limited success rates.

The mechanisms underlying these sustained therapeutic effects remain an active area of inquiry. Neurobiological studies suggest that psychedelics like psilocybin modulate the brain’s default mode network (DMN)—a set of interconnected regions implicated in self-referential thought and rumination. Psilocybin appears to transiently disrupt rigid DMN activity, promoting neural plasticity and heightened emotional processing that may facilitate the psychological breakthroughs observed in therapy. Additionally, psychedelics induce profound alterations in consciousness, fostering experiences of ego dissolution, interconnectedness, and meaning that may underpin the rapid and enduring clinical benefits.

Dr. Ross’s research portfolio also includes recent work on major depressive disorder (MDD). As senior author of a phase 2 multi-center clinical trial published in JAMA in 2023, he reported that a single dose of psilocybin-assisted psychotherapy elicited rapid, clinically significant, and sustained reductions in depressive symptoms. These data reinforce the potential for psychedelic therapies to complement or even supplant traditional antidepressants, which often require weeks to months to yield partial relief and carry burdensome side effect profiles.

Currently, Dr. Ross is spearheading the largest NIH-funded clinical trial of psilocybin therapy aimed at alleviating emotional and spiritual distress in cancer patients. This landmark funding marks a pivotal moment in the field, representing the first major NIH grant awarded to psychedelic research in more than 50 years. The study seeks not only to replicate earlier promising findings but also to establish a regulatory foundation for integrating psilocybin therapy into mainstream oncological and palliative care settings.

Furthermore, Dr. Ross is pioneering explorations of psychedelic therapy’s applicability beyond psychiatric diagnoses, including potential uses in treating chronic pain and addressing fear of cancer recurrence in early-stage breast cancer patients. These expansions reflect a broader conceptual evolution, wherein psychedelics are not merely repositioned as mental health agents but as modulators of complex biopsychosocial suffering patterns that span psychiatry, oncology, and pain medicine.

Despite his groundbreaking advances, Dr. Ross acknowledges the professional challenges that accompanied his commitment to psychedelic research. When he embarked on this path, several mentors cautioned him that his focus on psychedelics could derail his career, labeling the area a “road to nowhere.” Nevertheless, his perseverance highlights the importance of intellectual courage and resilience in the face of entrenched scientific skepticism and regulatory hurdles.

The ongoing mainstreaming of psychedelic therapies poses significant implications for healthcare systems. Integration into cancer centers, addiction treatment facilities, and palliative programs would necessitate new clinical infrastructures, including specialized training for therapists, development of ethical guidelines, and frameworks to ensure patient safety and accessibility. Dr. Ross’s work not only advances the scientific basis of these therapies but also illuminates the systemic changes required to translate research discoveries into widespread clinical practice.

Stephen Ross’s contributions exemplify the reawakening of psychedelic medicine as a frontier in mental health and broader medical care. His work, blending clinical acumen, rigorous trials, and compassionate application, redefines the potential for psychedelics to address some of the most intractable psychiatric and medical conditions. As regulatory landscapes evolve and public acceptance grows, his research paves the way for a paradigm shift that could reshape psychiatry and oncology, bringing hope and healing through experiences “hidden in plain sight” for decades.

Subject of Research: People

Article Title: Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders

News Publication Date: 10-Jun-2025

Web References:
http://dx.doi.org/10.61373/pp025k.0017

Image Credits: Stephen Ross, MD

Keywords: Psychedelic medicine, psilocybin, psychiatric disorders, cancer-related distress, psychedelic-assisted psychotherapy, substance use disorder, major depressive disorder, neurobiology, default mode network, clinical trials, NIH-funded research, psychedelic therapy integration